Unfortunately, in recent years, there has been an increase in cases of breast cancer detected in women. Even if the tumour is found at an early stage and successfully removed, there remains a risk of recurrence, and to exclude the possibility of a second cancer, the patient undergoes a course of hormonal therapy. However, no hormonal therapy provides a 100% guarantee. On the other hand, even the most advanced hormonal therapy is a serious trial for the body.
How can one know if there is a risk of recurrence after the removal of a breast tumour?
Recently, the latest molecular biological test Prosigna has been introduced in Israel, which provides the most accurate answer to these questions with a guarantee of more than 10 years. This test is much more reliable than all currently available methods of molecular biological diagnostics. Specialists at the Top Ihilov clinic conduct the Prosigna test at the highest level, using the most modern equipment and within just a few days.
Only the Prosigna test combines the study of the genetic profile, tumour size, and the level of cancer cell spread.
Prosigna – a guarantee of accurate results
The method is approved by the U.S. Food and Drug Administration (FDA) and European quality control structures for medical services, and its high effectiveness and reliability have been proven by numerous clinical trials.
Who is the Prosigna test conducted for?
The test is conducted for patients who have had an early-stage breast tumour removed and who are postmenopausal, with the presence of estrogen and progesterone receptors (ER, PR), that is, in cases of hormone-dependent cancer.
How does the Prosigna test work?
This is the only test in the world that helps to express the risk of breast cancer recurrence with high accuracy in percentage terms, with a guarantee of more than 10 years. The test studies 50 genes (PAM50 profile). Depending on the percentage of risk, patients are divided into 3 groups: low, medium, and high risk. The test examines 4 molecular subtypes of breast cancer: Luminal A, Luminal B, Basal-Like, and HER2 Enriched. Thus, the test considers all aspects of tumour biology, allowing for accurate conclusions about the type of desired treatment and the possibility of recurrence.
The referral for the test is given by an oncologist, and the material for it is a fragment of the tumour tissue removed during surgery. Testing takes only a few days and is conducted using the innovative nCounter device developed by the renowned company Nanostring Technologies.
- Breast cancer